pyrroles has been researched along with Brill-Symmers Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Arenas, F; Balagué, O; Campo, E; Capdevila, C; Carreras, J; Cid, MC; Colomer, D; Guerrero-Hernández, M; Hernández, L; López-Guillermo, A; Magnano, L; Martin, S; Matas-Céspedes, A; Pérez-Galán, P; Rivas-Delgado, A; Rodriguez, V; Serrat, N; Tannheimer, S; Valero, JG; Yahiaoui, A | 1 |
| Bejot, C; Berger, M; Feldman, T; Ford, P; Fung, HC; Goy, A; Mato, A | 1 |
| Bhat, S; Brem, EA; Campagna, R; Czuczman, MS; Deeb, G; Fetterly, G; Gibbs, JF; Gu, J; Hernandez-Ilizaliturri, FJ; Hoskin, P; Iqbal, A; Khubchandani, S; Knight, J; Mavis, C; Olejniczak, SH; Riaz, W; Thudium, K; Tsai, PC | 1 |
3 other study(ies) available for pyrroles and Brill-Symmers Disease
| Article | Year |
|---|---|
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma.
Topics: Aminopyridines; Animals; Apoptosis; Biomarkers, Tumor; Cell Differentiation; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Macrophages; Mice; Monocytes; Phosphorylation; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; Indoles; Lymphoma, Follicular; Pyrroles; Rituximab; Treatment Outcome | 2014 |
Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.
Topics: Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Autophagy; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspases; Cell Death; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Rituximab; Tumor Cells, Cultured; Up-Regulation | 2011 |